$Acelyrin (SLRN.US)$MT Newswires· 2 mins ago Acelyrin (SLRN) said Thursday that the global late-stage trial of its treatment izokibep in patients with moderate-to-severe hidradenitis suppurativa yielded statistically significant improvement responses across multiple efficacy endpoints.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more